bioAffinity reports CyPath Lung sales up over 100% through Q3 2026

bioAffinity Technologies, Inc.

CyPath Lung sales rose more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in Q3 2025.
Ordering physicians increased 89% in Q3 2026 versus Q3 2025; prior prescribers' sales volume rose 48% year-over-year.
CEO Maria Zannes cited a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach in government healthcare, including the Department of Veterans Affairs.
CyPath Lung reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with nodules under 20 mm.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.